We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

A big molecule to swallow

23 April 2007 By Una Galani

The UK pharma paid 25% more than the market expected to win the auction for the US biotech MedImmune. That s the price of potential growth. Astrazeneca is paying 12 times revenues, but sees huge synergies. And biotech could help solve its own growth problem.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)